TMCnet News
Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors– Series B proceeds will fund clinical proof-of-biology studies of SARM1 inhibitors – First patient dosed in Phase 1b/2a ALS study with NB-4746, an oral, brain-penetrant SARM1 inhibitor – Dosing initiated in a first-in-human study of NB-9402, a next-generation, first-in-class covalent allosteric SARM1 inhibitor SOUTH SAN FRANCISCO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Nura Bio Inc. (Nura Bio), a clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies, today announced the completion of a $73.8M Series B financing and the advancement of its two clinical-stage SARM1 inhibitor programs. The financing, led by The Column Group, with participation from Euclidean Capital, Samsara BioCapital, and Sanofi Ventures, will fund the development of Nura Bio’s clinical pipeline, including the Phase 1b/2a study of NB-4746, its oral, brain-penetrant SARM1 inhibitor, which recently commenced dosing in ALS patients. “With no cure and few effective, disease-modifying therapies, ALS remains a devastating disease,” said Prof. Jeremy Shefner, MD PhD, Professor in the Department of Neurology at Barrow Neurological Institute and neurologist in the Gregor W. Fulton ALS & Neuromuscular Disease Center. “Nura Bio has been at the forefront of developing neuroprotective therapies targeting SARM1, a protein with a well-defined role in axon degeneration. The advancement of this program represents an important step toward elucidating the potential therapeutic benefit of SARM1 inhibition for ALS patients." NB-4746 has been shown to prevent axon degeneration driven by the SARM1 protein, providing neuroprotection in multiple preclinical models of nerve injury and disease, including ALS. In a Phase 1 study in healthy volunteers, NB-4746 demonstrated a favorable safety profile and achieved target plasma and cerebrospinal fluid exposure levels. Building on its leadership in SARM1-targeted therapies, Nura Bio has also commenced dosing of an oral, covalent, allosteric SARM1 inhibitor, NB-9402, in a first-in-human study. NB-9402 has demonstrated high potency and long-lasting efficacy in preclinical models of neurological diseases. “With NB-4746 actively enrolling ALS patients in a Phase 1b/2a study and the rapid advancement of NB-9402, our next generation covalent allosteric SARM1 inhibitor, into a Phase 1a study, we have built a portfolio of SARM1 inhibitors uniquely positioned to fully explore and validate the broad therapeutic potential of this target,” said Shilpa Sambashivan, CEO of Nura Bio. “This progress reinforces our commitment to pursuing ground-breaking science and developing transformative therapies for people with life-threatening neurological diseases.” About NB-4746 and NB-9402 About Nura Bio Contact: 
|